Mineralys Therapeutics shared new results showing lorundrostat significantly lowered blood pressure and was well-tolerated.

MLYS · Mineralys Therapeutics

The AI's read

The sustained blood-pressure change and lack of new safety findings strengthen the case for lorundrostat. The study was an open-label extension, so it does not show how the drug compares with a control group. The drug is still in clinical testing, leaving its later success uncertain.